Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

Tags: ASCO GU Conference CoverageProstate

Published: 23 February 2019

Recent Videos: ASCO GU Conference Coverage

video

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment ...

video

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, offers opinion on whether patients in the first line setting should ...

video

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone ...

video

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look ...

video

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination ...

video

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, tell us about the results of KEYNOTE 365 investigating the use ...

video

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on how androgen deprivation therapy (ADT) is changing for men ...

video

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer ...

Related Videos

video-image

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

video-image

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

video-image

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

video-image

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

video-image

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

video-image

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC

video-image

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

video-image

Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC

video-image

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

video-image

Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC

video-image

Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

video-image

Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study

video-image

Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer

video-image

Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019

video-image

Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer

video-image

Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC

video-image

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

video-image

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

video-image

Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer

video-image

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer

video-image

Mark T. Fleming, MD, regarding the Aramis study in prostate cancer

video-image

Yair Lotan, MD, on molecular characterization & subtyping data in bladder cancer

video-image

Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC

video-image

Yair Lotan, MD, considers the latest in screening for high-risk asymptomatic bladder cancer

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

video-image

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

video-image

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

video-image

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

video-image

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

video-image

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

video-image

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

video-image

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

video-image

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

video-image

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

video-image

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Daniel P. Petrylak, MD, offers opinion on the POUT study presented at ASCO GU 2018

video-image

Daniel P. Petrylak, MD, on molecular characterization & bladder subtyping in bladder cancer

video-image

Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer

video-image

Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC

video-image

Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment

video-image

Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, outlines the results of the POUT study presented at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, on molecular characterization & bladder subtyping data

video-image

Peter C. Black, MD, FACS, FRCSC, regarding checkpoint blockade in non-muscle invasive bladder cancer

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

Thomas Powles, MD, MBBS, MRCP, regarding immunotherapy & chemotherapy combinations in bladder cancer

video-image

William K. Oh, MD, on abiraterone acetate fine particle formulation

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Peter C. Black, MD, FACS, FRCSC, on impact of The Cancer Genome Atlas Project in bladder cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer

video-image

Daniel P. Petrylak, MD, outlines overall survival and immune responses from the STRIDE study

video-image

Daniel P. Petrylak, MD, on the Phase I data of enfortumab vedotin in mUC patients from ASCO GU 2018

video-image

Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC

video-image

Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer

video-image

Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC

video-image

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

video-image

Peter C. Black, MD, FACS, FRCSC, considers preferred checkpoint inhibitors for urothelial carcinoma

video-image

Peter C. Black, MD, FACS, FRCSC, on the usefulness of molecular markers in bladder cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

Thomas Powles, MD, MBBS, MRCP, on the evolving landscape of metastatic bladder cancer

video-image

Thomas Powles, MD, MBBS, MRCP, considers molecular markers and muscle-invasive bladder cancer

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

video-image

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

video-image

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

video-image

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

video-image

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

video-image

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

video-image

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

video-image

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

video-image

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

video-image

Evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone

video-image

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer ASCO GU 2016

video-image

Using new therapies earlier in prostate cancer may returns better results

video-image

Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium

video-image

Avelumab tolerable for patients according to JAVELIN Solid Tumor phase Ib trial

video-image

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

video-image

Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC - Dr. Walter Stadler

video-image

Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

video-image

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

video-image

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

video-image

Tomasz M. Beer MD, FACP, considers the role of metformin in castrate-resistant prostate cancer

video-image

Tomasz M. Beer MD, FACP, on the efficacy of abiraterone + enzalutamide in mCRPC

video-image

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

video-image

Nancy A. Dawson, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Tomasz M. Beer MD, FACP, tells us about the ENZAMET study in mHSPC

video-image

Nancy A. Dawson, MD, regarding the ENZAMET study in mHSPC presented at ASCO '19

video-image

William Oh, MD, tells us about the results of Keynote-365 in mCRPC

video-image

William Oh, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

William Oh, MD, considers the role of biomarker selection trials in prostate cancer

video-image

William Oh, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

video-image

Kim Chi, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Kim Chi, MD, provides perspective on biomarker selection trials in prostate cancer

video-image

Kim Chi, MD, regarding the TITAN study presented at ASCO 2019

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi

video-image

Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated